Etienne Lengliné
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Etienne Lengliné has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
Elie Azoulay
Medical Intensive Care Unit, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France
10 shared publicationsEmmanuel Raffoux
Hematology Department, Saint-Louis Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
10 shared publicationsVirginie Lemiale
Medical Intensive Care Unit, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France
9 shared publications- Sylvie Chevret
ECSTRRA Team, IRSL, INSERM UMR1342, Université Paris Cité, Paris, France
7 shared publications - Nicolas Boissel
Hôpital Saint-Louis, AP-HP, Paris, France
6 shared publications Emmanuel Canet
A Medical Intensive Care Unit , Hôpital Saint-Louis, APHP, Université Paris Diderot , Paris , France
5 shared publications
Latest Publications
- 19 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (2) , 817-820
Health‐related quality of life reporting in randomized controlled trials of chimeric antigen receptor T‐cell therapy: A systematic review of dedicated publications
- 19 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (2) , 817-820
Health‐related quality of life reporting in randomized controlled trials of chimeric antigen receptor T‐cell therapy: A systematic review of dedicated publications
- 24 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (7) , 1527-1536
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred
In the hematology-oncology settings, treatment effect is commonly measured from a randomized clinical trial (RCT) on right-censored outcomes, such as overall survival (OS), event-free survival (EFS...
- 24 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (7) , 1527-1536
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred
In the hematology-oncology settings, treatment effect is commonly measured from a randomized clinical trial (RCT) on right-censored outcomes, such as overall survival (OS), event-free survival (EFS...
- 18 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (25) , 3036-3049
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL
T-cell acute lymphoblastic leukemia (T-ALL) represents a group of aggressive hematological malignancies characterized by unfavorable prognosis, urging the need for innovative therapeutic strategies. LEF1 is a member of the lymphoid enhancer factor (LEF)/T-cell factor family of DNA-binding transcription factors, known for their interaction with nuclear β-catenin in the context of the Wnt signaling pathway. Although the implication of LEF1 in colon cancer is well documented, its clinical relevance and functional consequences remain elusive in T-ALL. In this study, we provide valuable insights into the prevalence and significance of LEF1 alterations in a comprehensive cohort of 474 pediatric and adult patients with T-ALL enrolled in the FRALLE-2000 (French group for childhood ALL) and GRAALL 2003-2005 (Group for Research on Adult Acute Lymphoblastic Leukemia) trials, respectively. LEF1 alterations were detected in 63 cases (13%), including 9 point mutations (14.3%), 18 large deletions (28.6%), and, strikingly, 36 focal deletions (57.1%), which emerge as the most recurrent subtype. LEF1-altered cases were associated with increased central nervous system involvement and improved initial treatment response. Importantly, we unveil the existence of a previously undescribed dominant-negative LEF1 isoform resulting from focal deletions of the exons 2-3. This novel truncated protein, previously unreported in the literature, is associated with the disruption of the Wnt pathway and T-cell receptor signaling, which can be exploited as a therapeutic strategy to enhance chemosensitivity in LEF1-deleted T-ALL cases. The trials were registered at www.clinicaltrials.gov as #NCT00222027 (GRAALL 2003) and #NCT00327678 (GRAALL 2005); FRALLE2000T protocol (FRALLE-2000).
- 18 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (25) , 3036-3049
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL
T-cell acute lymphoblastic leukemia (T-ALL) represents a group of aggressive hematological malignancies characterized by unfavorable prognosis, urging the need for innovative therapeutic strategies. LEF1 is a member of the lymphoid enhancer factor (LEF)/T-cell factor family of DNA-binding transcription factors, known for their interaction with nuclear β-catenin in the context of the Wnt signaling pathway. Although the implication of LEF1 in colon cancer is well documented, its clinical relevance and functional consequences remain elusive in T-ALL. In this study, we provide valuable insights into the prevalence and significance of LEF1 alterations in a comprehensive cohort of 474 pediatric and adult patients with T-ALL enrolled in the FRALLE-2000 (French group for childhood ALL) and GRAALL 2003-2005 (Group for Research on Adult Acute Lymphoblastic Leukemia) trials, respectively. LEF1 alterations were detected in 63 cases (13%), including 9 point mutations (14.3%), 18 large deletions (28.6%), and, strikingly, 36 focal deletions (57.1%), which emerge as the most recurrent subtype. LEF1-altered cases were associated with increased central nervous system involvement and improved initial treatment response. Importantly, we unveil the existence of a previously undescribed dominant-negative LEF1 isoform resulting from focal deletions of the exons 2-3. This novel truncated protein, previously unreported in the literature, is associated with the disruption of the Wnt pathway and T-cell receptor signaling, which can be exploited as a therapeutic strategy to enhance chemosensitivity in LEF1-deleted T-ALL cases. The trials were registered at www.clinicaltrials.gov as #NCT00222027 (GRAALL 2003) and #NCT00327678 (GRAALL 2005); FRALLE2000T protocol (FRALLE-2000).
- Open Access
- 9 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (1) , e72
How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies
Antimicrobial resistance (AMR) has become a worldwide growing concern over the past decades. Thus, encouraging manufacturers to develop new antibiotics is needed. We hypothesised that transparency on the regulatory appraisals of antibiotics would provide an incentive to pharmaceutical development. We thus aimed at reporting the French health technology assessment (HTA) opinions and reimbursement decision on antibiotics to those German (G-BA) and English (NICE) HTA bodies. A qualitative analysis of the Transparency Committee of the French National Authority for Health (TC-HAS) opinions regarding antibiotics assessment between 2016 and 2020 was performed. Decisions of reimbursement by TC-HAS were compared to those from G-BA and NICE when available. TC-HAS recognized a clinical benefit (CB) for 15/15 evaluated indications, a clinical added value for 9/15, and a public health interest for 8/15. Among the valued antibiotics by HAS, 5 were recommended for restricted use as a “reserve” to protect against the risk of resistance emergence. A comparison of HTA opinions was possible across HTA for only 8 antibiotics. The G-BA granted a reserve status for 4 drugs and NICE a reserve with restricted use for 5 antibiotics. Three of these antibiotics were positioned similarly by the English, German, and French HTA bodies. This qualitative analysis of HTA opinions between different European HTA bodies shows a consistent reimbursement decision of antibiotics against MDR bacteria and tuberculosis besides the differences in the applied assessment methods. This work also shows how HTA bodies could recognize a clinical added value in a context of the emergence of antibiotic resistance.
- 9 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (1) , e72
Open AccessHow do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies
Antimicrobial resistance (AMR) has become a worldwide growing concern over the past decades. Thus, encouraging manufacturers to develop new antibiotics is needed. We hypothesised that transparency on the regulatory appraisals of antibiotics would provide an incentive to pharmaceutical development. We thus aimed at reporting the French health technology assessment (HTA) opinions and reimbursement decision on antibiotics to those German (G-BA) and English (NICE) HTA bodies. A qualitative analysis of the Transparency Committee of the French National Authority for Health (TC-HAS) opinions regarding antibiotics assessment between 2016 and 2020 was performed. Decisions of reimbursement by TC-HAS were compared to those from G-BA and NICE when available. TC-HAS recognized a clinical benefit (CB) for 15/15 evaluated indications, a clinical added value for 9/15, and a public health interest for 8/15. Among the valued antibiotics by HAS, 5 were recommended for restricted use as a “reserve” to protect against the risk of resistance emergence. A comparison of HTA opinions was possible across HTA for only 8 antibiotics. The G-BA granted a reserve status for 4 drugs and NICE a reserve with restricted use for 5 antibiotics. Three of these antibiotics were positioned similarly by the English, German, and French HTA bodies. This qualitative analysis of HTA opinions between different European HTA bodies shows a consistent reimbursement decision of antibiotics against MDR bacteria and tuberculosis besides the differences in the applied assessment methods. This work also shows how HTA bodies could recognize a clinical added value in a context of the emergence of antibiotic resistance.
- 5 September 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (10) , 1127-1130
Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia
Tyrosine kinase inhibitors efficacy in central nervous system (CNS) disease remains uncertain. Ponatinib was studied for CNS distribution in 16 patients with Philadelphia-positive acute lymphoblastic leukemia. Cerebrospinal fluid concentrations fell below the 40 nM threshold, suggesting suboptimal CNS exposure.
- 5 September 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (10) , 1127-1130
Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia
Tyrosine kinase inhibitors efficacy in central nervous system (CNS) disease remains uncertain. Ponatinib was studied for CNS distribution in 16 patients with Philadelphia-positive acute lymphoblastic leukemia. Cerebrospinal fluid concentrations fell below the 40 nM threshold, suggesting suboptimal CNS exposure.
- Open Access
- 20 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (10) , 2405-2409
Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
- 20 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (10) , 2405-2409
Open AccessBlinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
- Open Access
- 12 April 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 204, 114047
Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS)
- 12 April 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 204, 114047
Open AccessComposite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS)
- 3 January 2024
- Published by Elsevier in Bulletin du Cancer
- Vol. 111 (2) , 228-234
La Commission de la transparence de la Haute Autorité de santé
- 3 January 2024
- Published by Elsevier in Bulletin du Cancer
- Vol. 111 (2) , 228-234
La Commission de la transparence de la Haute Autorité de santé
- Open Access
- 27 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5680-5690
Enriching single-arm clinical trials with external controls: possibilities and pitfalls
For the past decade, it has become commonplace to provide rapid answers and early patient access to innovative treatments in the absence of randomized clinical trials (RCT), with benefits estimated from single-arm trials. This trend is important in oncology, notably when assessing new targeted therapies. Some of those uncontrolled trials further include an external/synthetic control group as an innovative way to provide an indirect comparison with a pertinent control group. We aimed to provide some guidelines as a comprehensive tool for (1) the critical appraisal of those comparisons or (2) for performing a single-arm trial. We used the example of ciltacabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 3 or more treatment lines as an illustrative example. We propose a 3-step guidance. The first step includes the definition of an estimand, which encompasses the treatment effect and the targeted population (whole population or restricted to single-arm trial or external controls), reflecting a clinical question. The second step relies on the adequate selection of external controls from previous RCTs or real-world data from patient cohorts, registries, or electronic patient files. The third step consists of choosing the statistical approach targeting the treatment effect defined above and depends on the available data (individual-level data or aggregated external data). The validity of the treatment effect derived from indirect comparisons heavily depends on careful methodological considerations included in the proposed 3-step procedure. Because the level of evidence of a well-conducted RCT cannot be guaranteed, the evaluation is more important than in standard settings.
- 27 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5680-5690
Open AccessEnriching single-arm clinical trials with external controls: possibilities and pitfalls
For the past decade, it has become commonplace to provide rapid answers and early patient access to innovative treatments in the absence of randomized clinical trials (RCT), with benefits estimated from single-arm trials. This trend is important in oncology, notably when assessing new targeted therapies. Some of those uncontrolled trials further include an external/synthetic control group as an innovative way to provide an indirect comparison with a pertinent control group. We aimed to provide some guidelines as a comprehensive tool for (1) the critical appraisal of those comparisons or (2) for performing a single-arm trial. We used the example of ciltacabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 3 or more treatment lines as an illustrative example. We propose a 3-step guidance. The first step includes the definition of an estimand, which encompasses the treatment effect and the targeted population (whole population or restricted to single-arm trial or external controls), reflecting a clinical question. The second step relies on the adequate selection of external controls from previous RCTs or real-world data from patient cohorts, registries, or electronic patient files. The third step consists of choosing the statistical approach targeting the treatment effect defined above and depends on the available data (individual-level data or aggregated external data). The validity of the treatment effect derived from indirect comparisons heavily depends on careful methodological considerations included in the proposed 3-step procedure. Because the level of evidence of a well-conducted RCT cannot be guaranteed, the evaluation is more important than in standard settings.
- 16 February 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (7) , 691-692
C1q helps AML to disseminate and resist
In this issue of Blood, Yang et al1 identified that the complement component 1q (C1q) may facilitate both the dissemination of acute myeloid leukemia (AML) outs
- 16 February 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (7) , 691-692
C1q helps AML to disseminate and resist
In this issue of Blood, Yang et al1 identified that the complement component 1q (C1q) may facilitate both the dissemination of acute myeloid leukemia (AML) outs